# Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Canonical URL: https://biopharmsignal.com/news/ALKS/alkermes-showcases-data-from-psychiatry-portfolio-and-sleep-research-into-real-world-patient-experience-at-spring-2026-scientific-conferences
Ticker: ALKS
Company: Alkermes plc
Source: Alkermes plc
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.alkermes.com
## Summary

– Real-World Evidence of Positive Impact of LYBALVI ® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation Highlights Recent Clinical Data, Including Results for Negative

## Article Body
– Real-World Evidence of Positive Impact of LYBALVI ® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation Highlights Recent Clinical Data, Including Results for Negative
## Recent Company News
- 2026-06-25 13:46 EST — [Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026](https://biopharmsignal.com/news/ALKS/alkermes-presents-detailed-positive-results-from-vibrance-2-phase-2-study-of-alixorexton-in-adults-with-narcolepsy-type-2-at-sleep-2026) — Source: Alkermes plc
- 2026-06-25 13:46 EST — [Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe](https://biopharmsignal.com/news/ALKS/alkermes-announces-orphan-drug-designations-for-alixorexton-in-the-u-s-and-europe) — Source: Alkermes plc
- 2026-06-25 13:46 EST — [Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research](https://biopharmsignal.com/news/ALKS/alkermes-to-present-new-data-on-alixorexton-and-lumryzr-sodium-oxybate-at-sleep-2026-highlighting-breadth-of-sleep-medicine-research) — Source: Alkermes plc
- 2026-06-25 13:46 EST — [Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ALKS/alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Alkermes plc
- 2026-06-25 13:46 EST — [Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting](https://biopharmsignal.com/news/ALKS/alkermes-to-showcase-leadership-in-psychiatry-and-orexin-biology-with-new-data-at-the-american-society-of-clinical-psychopharmacology-annual-meeting) — Source: Alkermes plc
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)